Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 1

Conditions

Recurrence 1Glioma 1Extensive Stage Lung Small Cell Carcinoma 1

Interventions

pembrolizumab 589Cyclophosphamide 539Magnetic Resonance Spectroscopy 523Radiotherapy 506Specimen Handling 503Nivolumab 407Cisplatin 370Carboplatin 358Biopsy 304Blood Specimen Collection 295Radiosurgery 283Paclitaxel 274Surveys and Questionnaires 268Standard of Care 266Gemcitabine 265fludarabine 261Dexamethasone 258Drug Therapy 256venetoclax 246Bevacizumab 246Oxaliplatin 206Rituximab 195Capecitabine 194Radiation 189Fluorouracil 186Ipilimumab 184durvalumab 180Doxorubicin 175atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Lamivudine × 1 year × Clear all
NCT06494579 2025-12-16

Lamivudine for Solid Tumors

Icahn School of Medicine at Mount Sinai

Phase 1/2 Active not recruiting
12 enrolled

Recurrence

NCT04696575 2025-12-15

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

Roswell Park Cancer Institute

Phase 2 Recruiting
28 enrolled

Extensive Stage Lung Small Cell Carcinoma

NCT06428045 2025-06-22

STARLITE

University of Miami

Phase 1 Recruiting
24 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡